Gilead Publishes 2015 Corporate Social Responsibility Report
Foster City, CA, August 1, 2016 – Gilead Sciences, Inc. today announced that it issued its first Corporate Social Responsibility Report, which provides an overview of the work the company is doing around the world to improve the lives of people with life-threatening diseases and to make a positive impact on public health and local communities.
“A genuine sense of corporate citizenship has long been at the heart of everything we do,” said John Milligan, PhD, President and Chief Executive Officer, Gilead Sciences. “As CEO, my vision for Gilead is to continue to innovate at every level – delivering lifesaving medicines to patients and making a positive contribution to all of the communities we serve and of which we are a part.”
The report focuses on four key areas of Giving and Access, People, Products and Environment. 2015 highlights from each of these include:
- Giving & Access: In 2015, Gilead donated nearly $500 million to almost 2,000 organizations worldwide that are helping to address unmet medical needs and lessen the impact of disease such as HIV and viral hepatitis. Last year, Gilead was named the number one funder in terms of charitable donations among Fortune 150 companies by The Chronicle of Philanthropy.
- People: Gilead added 900 jobs around the world in 2015, more than doubling the company’s overall workforce since 2010 and surpassing 8,200 employees in total.
- Products: Many of Gilead’s products are category firsts or are among the leading medicines used to treat the diseases they address. With 20 marketed products by the end of 2015, Gilead produced more than 900 million tablets of oral medicines and approximately 9 million vials of liquid medicine last year.
- Environment: At the Foster City, California headquarters, Gilead drove a 23 percent reduction in landscape water use in 2015 compared with a 2013 baseline, far exceeding the city mandate of 12 percent reduction.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world, always keeping the patients and the communities we serve at the forefront.